NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

Kemas kini terakhir: 25 Nov, 8:17PM

47.06

2.09 (4.65%)

  • 1H 4.65%
  • 5H -4.64%
  • 1B 2.44%
  • 6B -37.64%
  • Tahun Ke Tarikh -46.23%
  • 1T -57.63%
  • 5T 37.24%
Penutupan Terdahulu 44.97
Buka 45.98
Jumlah Dagangan 30,448,243
Purata Dagangan (3B) 16,098,220
Modal Pasaran 209,110,155,264
Harga / Pendapatan (P/E TTM) 12.52
Harga / Pendapatan (P/E Ke hadapan) 14.08
Harga / Jualan (P/S) 4.33
Harga / Buku (P/B) 8.03
Julat 52 Minggu
43.08 (-8%) — 112.52 (139%)
Tarikh Pendapatan 4 Feb 2026
Hasil Dividen (DY TTM) 2.34%
Margin Keuntungan 34.51%
Margin Operasi (TTM) 49.68%
EPS Cair (TTM) 3.67
Pertumbuhan Hasil Suku Tahunan (YOY) 19.50%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 14.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 85.70%
Nisbah Semasa (MRQ) 0.740
Aliran Tunai Operasi (OCF TTM) 131.24 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 77.73 B
Pulangan Atas Aset (ROA TTM) 23.29%
Pulangan Atas Ekuiti (ROE TTM) 88.12%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menurun
Drug Manufacturers - General (Global) Menaik Menurun
Stok Novo Nordisk A/S Menurun Menurun

AISkor Stockmoo

-0.8
Konsensus Penganalisis -0.5
Aktiviti Orang Dalam NA
Volatiliti Harga 4.5
Purata Bergerak Teknikal -5.0
Osilator Teknikal -2.0
Purata -0.75

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
NVO 209 B 2.34% 12.52 8.03
NVS 254 B 3.27% 18.08 5.79
LLY 906 B 0.15% 49.50 38.88
JNJ 486 B 0.62% 19.46 6.24
ABBV 404 B 1.43% 171.96 50.46
MRK 252 B 1.60% 13.36 4.90

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Core
% Dimiliki oleh Orang Dalam 0.01%
% Dimiliki oleh Institusi 9.85%

Pemilikan

Nama Tarikh Syer Dipegang
Everett Harris & Co /Ca/ 30 Sep 2025 6,393,780
Julat 52 Minggu
43.08 (-8%) — 112.52 (139%)
Julat Harga Sasaran
46.00 (-2%) — 70.00 (48%)
Tinggi 70.00 (HSBC, 48.75%) Beli
Median 50.50 (7.31%)
Rendah 46.00 (BMO Capital, -2.25%) Pegang
Purata 54.25 (15.28%)
Jumlah 2 Beli, 1 Pegang, 1 Jual
Harga Purata @ Panggilan 52.66
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Goldman Sachs 28 Nov 2025 54.00 (14.75%) Beli 49.35
BMO Capital 25 Nov 2025 46.00 (-2.25%) Pegang 47.06
14 Oct 2025 55.00 (16.87%) Pegang 56.66
HSBC 02 Oct 2025 70.00 (48.75%) Beli 58.74
Morgan Stanley 29 Sep 2025 47.00 (-0.13%) Jual 55.50

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
01 Dec 2025 CNBC Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
25 Nov 2025 Pengumuman Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes
24 Nov 2025 Pengumuman Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression
24 Nov 2025 CNBC Eli Lilly hits $1 trillion market value, a first in health care, as Novo Nordisk tumbles
17 Nov 2025 CNBC Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
17 Nov 2025 Pengumuman Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
14 Nov 2025 Pengumuman Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S
13 Nov 2025 Pengumuman Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
11 Nov 2025 Pengumuman Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08 Nov 2025 Pengumuman Novo Nordisk will not increase its proposal to acquire Metsera, Inc. 
07 Nov 2025 CNBC Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
07 Nov 2025 CNBC Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
06 Nov 2025 CNBC Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
06 Nov 2025 CNBC Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 
06 Nov 2025 Pengumuman Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
06 Nov 2025 Pengumuman Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
05 Nov 2025 Pengumuman Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
05 Nov 2025 Pengumuman Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications
04 Nov 2025 CNBC Metsera says Novo Nordisk’s new up to $10 billion bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
04 Nov 2025 CNBC Pfizer tops estimates, raises profit guidance even as sales fall
04 Nov 2025 Pengumuman /C O R R E C T I O N -- Metsera, Inc./
04 Nov 2025 Pengumuman Novo Nordisk submits updated proposal to acquire Metsera, Inc.
03 Nov 2025 CNBC Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
02 Nov 2025 CNBC Where the blockbuster weight loss drug market stands today — and what’s coming next
30 Oct 2025 Pengumuman Novo Nordisk submits proposal to acquire Metsera, Inc.
30 Oct 2025 Pengumuman Metsera Receives Unsolicited Proposal from Novo Nordisk
30 Oct 2025 CNBC Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
29 Oct 2025 CNBC Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
21 Oct 2025 Pengumuman Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors
21 Oct 2025 Pengumuman Notice convening an Extraordinary General Meeting of Novo Nordisk A/S
17 Oct 2025 CNBC Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
15 Oct 2025 Pengumuman Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
09 Oct 2025 Pengumuman Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
30 Sep 2025 Pengumuman SueWallSt Podcast Series Launches With Focus on Novo Nordisk A/S (NVO) Fraud Allegations
29 Sep 2025 Pengumuman Novo Nordisk A/S (NVO) Shareholders Get Answers in Latest SueWallSt Podcast
23 Sep 2025 CNBC Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
22 Sep 2025 CNBC Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
18 Sep 2025 Pengumuman Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study
17 Sep 2025 CNBC Eli Lilly pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial
17 Sep 2025 Pengumuman Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
16 Sep 2025 CNBC Eli Lilly to build $5 billion Virginia facility to boost production of targeted cancer drugs, other treatments
16 Sep 2025 Pengumuman Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme
15 Sep 2025 Pengumuman EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
15 Sep 2025 Pengumuman People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being
12 Sep 2025 CNBC Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
11 Sep 2025 CNBC Health care inflation rises as patients, employers brace for biggest jump in health spending in 15 years
10 Sep 2025 Pengumuman Novo Nordisk to streamline operations and reinvest for growth
Papar semua
Hasil Dividen (DY TTM) 2.34%
Purata Hasil Dividen 5T 2.48%
Nisbah Pembayaran 47.09%
Jangkaan Pembayaran Dividen Seterusnya Apr 2026
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
31 Mar 2025 05 Feb 2025 08 Apr 2025 1.099206 Tunai
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 Tunai
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 Tunai
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 Tunai
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 Tunai
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 Tunai
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 Tunai
16 Aug 2021 - 25 Aug 2021 0.5502889 Tunai
26 Mar 2021 - 07 Apr 2021 0.922122 Tunai
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 Tunai
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 Tunai
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 Tunai
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 Tunai
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 Tunai
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 Tunai
17 Aug 2017 - 29 Aug 2017 0.33589 Tunai
23 Mar 2017 - 04 Apr 2017 0.479369 Tunai
11 Aug 2016 - 23 Aug 2016 0.331026 Tunai
18 Mar 2016 - 30 Mar 2016 0.69943 Tunai
19 Mar 2015 - 31 Mar 2015 0.532885 Tunai
21 Mar 2014 - 02 Apr 2014 0.606122 Tunai
21 Mar 2013 - 02 Apr 2013 2.264307 Tunai
22 Mar 2012 - 03 Apr 2012 1.831902 Tunai
24 Mar 2011 - 05 Apr 2011 1.357901 Tunai
25 Mar 2010 - 07 Apr 2010 0.978615 Tunai
19 Mar 2009 - 31 Mar 2009 0.781532 Tunai
13 Mar 2008 - 25 Mar 2008 0.678462 Tunai
08 Mar 2007 - 20 Mar 2007 0.891779 Tunai
09 Mar 2006 - 21 Mar 2006 0.691753 Tunai
10 Mar 2005 - 22 Mar 2005 0.61725 Tunai
17 Mar 2004 - 29 Mar 2004 0.52096 Tunai
26 Mar 2003 - 07 Apr 2003 0.37647 Tunai
13 Mar 2002 - 25 Mar 2002 0.2848 Tunai
21 Mar 2001 - 02 Apr 2001 0.5681 Tunai
24 Mar 2000 - 06 Apr 2000 0.4672 Tunai
25 Mar 1999 - 06 Apr 1999 0.4182 Tunai
27 Mar 1998 - 08 Apr 1998 0.3051 Tunai
25 Apr 1997 - 07 May 1997 0.239 Tunai
01 May 1996 - 14 May 1996 0.1806 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.10 1 2.34
2024 1.44 2 1.68
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda